EQRx, Exscientia collaborate on AI-drug discovery

By The Science Advisory Board staff writers

June 24, 2021 -- EQRx and artificial intelligence (AI) pharmatech firm Exscientia have inked a research and development collaboration agreement under which they will work together to discover and develop small-molecule therapeutic drug candidates for oncology and immunology.

The collaboration will expand EQRx's novel therapies pipeline, according to the two firms. Exsicienta will lead the discovery phase through investigational new drug (IND) filing, and EQRx will take on the clinical development, regulatory, and marketing efforts. They will share costs, they said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.